Anika Therapeutics Inc
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +21.5% | +1.9% | +17.6% | -1.3% | +18.5% | +10.6% | -4.9% | +0.5% | -22.5% | -25.1% | -6.2% | |
| – | +26.9% | -3.4% | +21.1% | -1.6% | +15.5% | -24.3% | -5.0% | +0.6% | -3.7% | -30.4% | -9.1% | |
| – | +10.5% | -5.8% | +27.8% | -33.2% | +76.8% | -39.1% | -1.5% | -8.5% | -20.4% | -19.1% | +3.3% | |
| – | +29.5% | -9.9% | +26.0% | +1.1% | +16.3% | -46.8% | -4.0% | -8.5% | -20.4% | -19.1% | +3.3% | |
| – | +26.2% | +27.5% | -13.7% | -12.8% | +11.1% | +4.4% | +23.8% | +16.0% | -23.9% | -10.5% | +0.4% | |
| – | +20.4% | +7.0% | +37.9% | -3.3% | +3.3% | +110.1% | -22.1% | +10.4% | -38.6% | -2.5% | -21.1% | |
| – | +26.6% | +30.4% | +7.4% | -3.7% | -6.2% | -0.3% | -5.9% | +1.4% | – | – | – | |
| – | -10.3% | -3.6% | +13.9% | -4.5% | -2.0% | +9.3% | -7.5% | -5.7% | +3.2% | -5.9% | +13.0% | |
| – | -21.7% | -12.3% | +4.0% | -13.6% | -17.5% | +1,101.8% | -9.6% | -9.4% | -96.5% | -3.3% | -33.7% | |
| – | +56.6% | -29.8% | +9.5% | -19.6% | +175.2% | +120.2% | -35.1% | +5.2% | -8.2% | -16.5% | -4.0% | |
| – | +189.3% | -49.1% | +48.6% | -13.6% | +44.2% | +126.5% | -19.2% | -6.3% | +11.3% | -25.0% | -6.0% | |
| – | – | -27.3% | – | – | – | +38.9% | +8.1% | +20.9% | -11.9% | +5.0% | +7.0% | |
| – | +591.3% | -72.3% | +193.0% | -53.4% | +21.9% | +134.4% | -15.0% | +18.9% | -31.7% | -9.3% | +7.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +18.4% | +5.7% | +18.3% | +0.0% | +9.4% | -5.5% | +5.4% | -0.5% | -25.7% | -27.5% | -6.8% | |
| – | +29.3% | +24.0% | +18.6% | +9.4% | +12.5% | -9.8% | +1.9% | -6.6% | -39.2% | -44.0% | -15.2% | |
| – | +0.3% | -1.3% | -0.3% | -2.5% | -2.1% | -1.1% | +2.9% | -0.5% | +0.7% | +0.4% | -2.6% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.